Stellar
Biotechnologies, the leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), announced today the appointment of Gregory T. Baxter, Ph.D.
and Charles V. Olson, D.Sc. to the Company’s Scientific Advisory Board (SAB).
They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse,
Ph.D. and Andrew Saxon, M.D. on the SAB. An ongoing resource to provide
Stellar’s management with counsel and guidance, the SAB is comprised of
prominent scientists and physicians representing a range of disciplines
including immunology, molecular biology and biochemistry.
Dr. Gregory Baxter,
a member of Stellar’s Board of Directors since August 2012, is a Senior
Scientist in the Department of Clinical Drug Development for CCS Associates,
Inc. He also serves as Adjunct Associate Professor at Cornell University in the
College of Chemical Engineering and on the Founders Board of Stanford
University’s StartX Med Program. Dr. Baxter’s background spans both science and
business arenas including Program Director for the National Science Foundation
(NSF) Division of Industrial Innovation and Partnerships; Founder and CSO of
Hurel Corporation; Founder and CEO of Aegen Biosciences; and Research
Scientists for Molecular Devices Corporation. Dr. Baxter received his Ph.D. in
Biochemistry/Molecular Biology from the University of California, Santa
Barbara.
“It’s been
gratifying to be a part of Stellar’s corporate achievements this past year and
I look forward to contributing on the Company’s research front and in the
advancement of its C. diff immunotherapy program,” said Dr. Baxter.
Dr. Charles Olson is
a biotechnology industry professional with broad scientific and operational
experience, and specialization in manufacturing operations and process
development. Dr. Olson currently serves as Vice President of CMC and Technical
Operations for NGM Biopharmaceuticals and Vice President of Protein Sciences
for Anthera Pharmacetuicals. His background includes the positions of Senior VP
of Product Development and Operations for Nexbio Inc.; VP of Hayward Operations
for Cell Genesys; Senior Director of Manufacturing, Facilities and Process
Development for Biomarin Pharmaceuticals; and Director of Manufacturing
Sciences for Onyx Pharmaceuticals. Dr. Olson received his D.Sc. in Biochemistry
from Hawthorne University.
“This is an exciting
time for Stellar with its many promising commercial opportunities that the
Company has in its sights,” said Dr. Olson. “I am excited to join a team with
such a strong technology position, and I look forward to being a part of their
success.”
Frank Oakes,
Stellar’s president and CEO, said, “We are delighted to have both of these
biotechnology experts available to our internal teams and to advise our Board
of Directors as we advance corporate objectives and deliver on key research and
operational goals.”
For more
information, visit www.stellarbiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment